JPRN-jRCT2080221713未知2 期
A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CLINICAL PHARMACOLOGY, SAFETY, AND TOLERABILITY OF ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Patient with Schizophrenia as defined with DSM-IV-TR who meet all inclusion criteria and do not meet all exclusion criteria.
- •- Patients with a PANSS total score between 50 and 120, inclusive, at the baseline visit
- •- Patients who have been explained study objectives, methods and other aspects of study, and can give voluntary consent in writing
排除标准
- •- Patients of treatment resistant schizophrenia
- •- Patients with a primary active mental illness diagnosis other than schizophrenia
- •- Patients with a history of significant cardiovascular disease
- •- Patients with treated but uncontrolled hematological, hepatic, renal, respiratory, gastrointestinal, endocrine, or neurological diseases, or other clinically significant concomitant physical diseases
- •- Patients who had received other investigational drugs within 90 days prior to baseline
- •- Patients considered not to be eligible by the investigator
研究者
相似试验
进行中（未招募）
不适用
A PHASE II STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMAEUCTR2012-000087-15-ITFONDAZIONE NEOPLASIE SANGUE ONLUS
进行中（未招募）
不适用
A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIAFor the treatment of relapsed or refractory B-CLL.MedDRA version: 8.1Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2006-004469-32-SECelgene Corporation124
进行中（未招募）
1 期
A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIAFor the treatment of relapsed or refractory B-CLL.MedDRA version: 8.1 Level: LLT Classification code 10003946 Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2006-004469-32-GBCelgene Corporation124
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE R-MPT IN ADVANCED, RELAPSED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - R.MPTPatients with Multiple MyelomaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-007087-28-ITFONDAZIONE NEOPLASIE SANGUE ONLUS
进行中（未招募）
不适用
An open label multicenter phase 2 study for the initial evaluation of the tolerability of Birch pollen extract in patients suffering from atopic eczema and clinical relevant IgE-mediated sensitization against birch pollen.EUCTR2007-004876-38-DEETI Pharma GmbH